Can Keryx Continue Climbing?


Keryx Biopharmaceuticals stunned the market yesterday after releasing positive phase 3 data for its hyperphosphatemia drug Zerenex. Shares jumped around 75% after the news was released, and investors are still enjoying the newfound optimism surrounding this biotech company. Shares hopped another 40% today, but what caused this additional jump? What should investors watch for going forward? In this video, health care analyst Max Macaluso dives into these questions.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's chief investment officer has selected his No. 1 stock for this year. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." We invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

The article Can Keryx Continue Climbing? originally appeared on

Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.